
TeraRecon and FEops Announce Collaboration for Structural Heart Planning Procedures
TeraRecon, a clinical AI SaaS company for medical imaging, has joined forces with FEops to integrate FEops’ HEARTguide™ solution into its offerings. This partnership focuses on improving patient outcomes through the application of clinical AI technologies, particularly in the domain of structural heart planning procedures for Left Atrial Appendage (LAA) occlusion. FEops HEARTguide is a unique cloud-based procedure planning solution in the structural heart sector allowing physicians to virtually simulate various implant positions and sizes of FDA-approved LAA devices, facilitating the selection of the optimal size and position for individual patients.
Clinical evidence stemming from the randomized controlled PREDICT-LAA trial demonstrated the advantages of FEops’ digital twin-based planning for LAA closure. It has been shown to enhance procedure efficiency and outcomes compared to standard CT-based planning. A recent study published in the Journal of the American College of Cardiology from the PREDICT-LAA trial aimed to evaluate the impact of preprocedural computational modeling using HEARTguide on the efficiency and outcomes of transcatheter left atrial appendage (LAA) closure. In this prospective, multicenter, randomized trial, 200 patients were randomly assigned to two groups: standard planning or cardiac computed tomography (CT) simulation-based planning using Amplatzer Amulet, with computer simulations provided by FEops HEARTguide. Results showed that the composite primary endpoint, which included contrast leakage distal of the Amulet lobe and/or the presence of device-related thrombus (DRT), occurred in 41.8% of the standard group compared to 28.9% in the HEARTguide group. Furthermore, the HEARTguide group demonstrated improved procedural efficiency, with fewer Amulet devices used (103 vs. 118) and fewer device repositionings (104 vs. 195) compared to the standard group.
TeraRecon will integrate FEops’ technology into its existing suite of applications. TeraRecon is a leader in AI based imaging solutions with over 5,000 active installations in 74 countries. It offers AI based software imaging solutions for cardiology, neurology, and radiology.
Matthieu De Beule, CEO of FEops, expressed enthusiasm for the collaboration, highlighting the shared vision of leveraging technology to transform healthcare. The integration of FEops HEARTguide into TeraRecon’s platform aims to equip clinicians with an invaluable tool for delivering optimized care to patients with cardiovascular conditions.